Claims for Patent: 9,505,841

Summary for Patent: 9,505,841

Title:	Use of an anti-Ang2 antibody
Abstract:	A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.
Inventor(s):	Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR)
Assignee:	SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR)
Application Number:	14/446,199
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,505,841
Patent Claims:	1. A method of enhancing the efficacy of an anticancer agent, comprising administering an anti-cancer agent and an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the anti-Ang2 antibody or the antigen-binding fragment thereof specifically binds to Ang2 and forms a complex with a Tie2 receptor via Ang2; and the anti-Ang2 antibody or an antigen-binding fragment thereof binds to Q418, P419 or a combination of Q418 and P419 in human Ang2 of SEQ ID NO: 11; or binds to 2 to 20 contiguous amino acid residues of SEQ ID NO: 11 including Q418, P419 or a combination of Q418 and P419, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises: a first heavy chain complementarity determining region (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a second heavy chain complementarity determining region (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, a third heavy chain complementarity determining region (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3, a first light chain complementarity determining region (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a second light chain complementarity determining region (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a third light chain complementarity determining region (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6. 2. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases the activity of Tie2 by increasing phosphorylation of Tie2 receptor. 3. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases phosphorylation of at least one protein selected from the group consisting of Akt, eNOS, and MAPK1 42/44. 4. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9. 5. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof is produced from a hybridoma deposited with accession number KCLRF-BP-00295. 6. The method of claim 1, further comprising administering Ang2 to the subject. 7. The method of claim 1, wherein the anticancer agent is at least one selected from the group consisting of cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, carmustine, lomustine, dacarbazine, fluorouracil (5-FU), capecitabine, cytarabine, gemcitabine, methotrexate (MTX), mercaptopurine (6-MP), vinblastine, vincristine, vinorelvine, paclitaxel, docetaxel, etoposide topotecan, irinotecan, dactinomycin, doxorubicin, daunorubicin, mitomycin, bleomycin, imatinib, trastuzumab, cetuximab, gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, cabozantinib, pazopanib, regorafenib, vandetanib, ziv-afilibercept, prednisone, and 6-thioguanine (6-TG). 8. The method of claim 1, wherein the anti-cancer agent and anti-Ang2 antibody are administered simultaneously or sequentially in any order.

Details for Patent 9,505,841

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-09-17
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-09-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2033-09-17
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2033-09-17
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-09-17
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-09-17